Sumitomo Mitsui Trust Holdings Inc. Decreases Holdings in Humana Inc. (NYSE:HUM)

Sumitomo Mitsui Trust Holdings Inc. reduced its stake in Humana Inc. (NYSE:HUM) by 7.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 337,682 shares of the insurance provider’s stock after selling 27,433 shares during the period. Sumitomo Mitsui Trust Holdings Inc.’s holdings in Humana were worth $117,081,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Barlow Wealth Partners Inc. purchased a new stake in shares of Humana during the 4th quarter valued at about $1,977,000. Auxano Advisors LLC acquired a new stake in Humana in the fourth quarter valued at approximately $540,000. Intech Investment Management LLC lifted its position in shares of Humana by 46.2% during the fourth quarter. Intech Investment Management LLC now owns 42,287 shares of the insurance provider’s stock worth $19,359,000 after purchasing an additional 13,356 shares in the last quarter. AdvisorShares Investments LLC purchased a new position in shares of Humana in the fourth quarter valued at $421,000. Finally, Vest Financial LLC grew its holdings in Humana by 43.3% during the 4th quarter. Vest Financial LLC now owns 27,993 shares of the insurance provider’s stock valued at $12,815,000 after purchasing an additional 8,455 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Trading Down 3.2 %

NYSE:HUM opened at $362.85 on Thursday. The firm has a market capitalization of $43.72 billion, a P/E ratio of 22.59, a P/E/G ratio of 2.17 and a beta of 0.51. The business has a 50 day simple moving average of $345.69 and a 200 day simple moving average of $350.79. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.67. Humana Inc. has a 12-month low of $298.61 and a 12-month high of $530.54.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The company had revenue of $29.61 billion during the quarter, compared to the consensus estimate of $28.52 billion. During the same quarter in the previous year, the company posted $9.38 earnings per share. The company’s revenue for the quarter was up 10.7% compared to the same quarter last year. Equities research analysts predict that Humana Inc. will post 16.27 EPS for the current year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, June 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.98%. Humana’s dividend payout ratio (DPR) is presently 22.04%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Cantor Fitzgerald reiterated a “neutral” rating and issued a $360.00 price objective on shares of Humana in a report on Wednesday, June 12th. Argus cut Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, March 13th. Piper Sandler assumed coverage on Humana in a report on Wednesday, June 26th. They set an “overweight” rating and a $392.00 price objective on the stock. Royal Bank of Canada reduced their target price on Humana from $415.00 to $353.00 and set an “outperform” rating for the company in a research note on Thursday, April 25th. Finally, Wells Fargo & Company dropped their price target on shares of Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a research note on Monday, April 8th. Fourteen investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $409.55.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.